TY - JOUR
T1 - Tbx20 is required in mid-gestation cardiomyocytes and plays a central role in atrial development
AU - Boogerd, Cornelis J.
AU - Zhu, Xiaoming
AU - Aneas, Ivy
AU - Sakabe, Noboru
AU - Zhang, Lunfeng
AU - Sobreira, Debora R.
AU - Montefiori, Lindsey
AU - Bogomolovas, Julius
AU - Joslin, Amelia C.
AU - Zhou, Bin
AU - Chen, Ju
AU - Nobrega, Marcelo A.
AU - Evans, Sylvia M.
N1 - Funding Information:
Confocal microscopy was performed at the University of California, San Diego School of Medicine Microscopy Core Facility, which is supported by the grant P30 NS047101.
Funding Information:
This work was supported by the American Heart Association (13POST16480012) and the Netherlands Organization for Scientific Research (NWO, 825.10.016) to C.J. Boogerd, National Institutes of Health grants HL119967, HL114010, HL123857, HL128075, and HL118758 (to M.A. Nobrega) and HL123747, HL117649, and HL074066 (to S.M. Evans). J. Bogomolovas is supported by the European Commission’s Marie Skłodowska-Curie Individual Fellowship (Titin Signals, 656636).
Publisher Copyright:
© 2018 The Authors.
PY - 2018
Y1 - 2018
N2 - Rationale: Mutations in the transcription factor TBX20 (T-box 20) are associated with congenital heart disease. Germline ablation of Tbx20 results in abnormal heart development and embryonic lethality by embryonic day 9.5. Because Tbx20 is expressed in multiple cell lineages required for myocardial development, including pharyngeal endoderm, cardiogenic mesoderm, endocardium, and myocardium, the cell type-specific requirement for TBX20 in early myocardial development remains to be explored. Objective: Here, we investigated roles of TBX20 in midgestation cardiomyocytes for heart development. Methods and Results: Ablation of Tbx20 from developing cardiomyocytes using a doxycycline inducible cTnTCre transgene led to embryonic lethality. The circumference of developing ventricular and atrial chambers, and in particular that of prospective left atrium, was significantly reduced in Tbx20 conditional knockout mutants. Cell cycle analysis demonstrated reduced proliferation of Tbx20 mutant cardiomyocytes and their arrest at the G1-S phase transition. Genome-wide transcriptome analysis of mutant cardiomyocytes revealed differential expression of multiple genes critical for cell cycle regulation. Moreover, atrial and ventricular gene programs seemed to be aberrantly regulated. Putative direct TBX20 targets were identified using TBX20 ChIP-Seq (chromatin immunoprecipitation with high throughput sequencing) from embryonic heart and included key cell cycle genes and atrial and ventricular specific genes. Notably, TBX20 bound a conserved enhancer for a gene key to atrial development and identity, COUP-TFII/Nr2f2 (chicken ovalbumin upstream promoter transcription factor 2/ nuclear receptor subfamily 2, group F, member 2). This enhancer interacted with the NR2F2 promoter in human cardiomyocytes and conferred atrial specific gene expression in a transgenic mouse in a TBX20-dependent manner. Conclusions: Myocardial TBX20 directly regulates a subset of genes required for fetal cardiomyocyte proliferation, including those required for the G1-S transition. TBX20 also directly downregulates progenitor-specific genes and, in addition to regulating genes that specify chamber versus nonchamber myocardium, directly activates genes required for establishment or maintenance of atrial and ventricular identity. TBX20 plays a previously unappreciated key role in atrial development through direct regulation of an evolutionarily conserved COUPT-FII enhancer.
AB - Rationale: Mutations in the transcription factor TBX20 (T-box 20) are associated with congenital heart disease. Germline ablation of Tbx20 results in abnormal heart development and embryonic lethality by embryonic day 9.5. Because Tbx20 is expressed in multiple cell lineages required for myocardial development, including pharyngeal endoderm, cardiogenic mesoderm, endocardium, and myocardium, the cell type-specific requirement for TBX20 in early myocardial development remains to be explored. Objective: Here, we investigated roles of TBX20 in midgestation cardiomyocytes for heart development. Methods and Results: Ablation of Tbx20 from developing cardiomyocytes using a doxycycline inducible cTnTCre transgene led to embryonic lethality. The circumference of developing ventricular and atrial chambers, and in particular that of prospective left atrium, was significantly reduced in Tbx20 conditional knockout mutants. Cell cycle analysis demonstrated reduced proliferation of Tbx20 mutant cardiomyocytes and their arrest at the G1-S phase transition. Genome-wide transcriptome analysis of mutant cardiomyocytes revealed differential expression of multiple genes critical for cell cycle regulation. Moreover, atrial and ventricular gene programs seemed to be aberrantly regulated. Putative direct TBX20 targets were identified using TBX20 ChIP-Seq (chromatin immunoprecipitation with high throughput sequencing) from embryonic heart and included key cell cycle genes and atrial and ventricular specific genes. Notably, TBX20 bound a conserved enhancer for a gene key to atrial development and identity, COUP-TFII/Nr2f2 (chicken ovalbumin upstream promoter transcription factor 2/ nuclear receptor subfamily 2, group F, member 2). This enhancer interacted with the NR2F2 promoter in human cardiomyocytes and conferred atrial specific gene expression in a transgenic mouse in a TBX20-dependent manner. Conclusions: Myocardial TBX20 directly regulates a subset of genes required for fetal cardiomyocyte proliferation, including those required for the G1-S transition. TBX20 also directly downregulates progenitor-specific genes and, in addition to regulating genes that specify chamber versus nonchamber myocardium, directly activates genes required for establishment or maintenance of atrial and ventricular identity. TBX20 plays a previously unappreciated key role in atrial development through direct regulation of an evolutionarily conserved COUPT-FII enhancer.
KW - cell lineage
KW - epigenomics
KW - heart defects, congenital
KW - mutation
KW - myocytes, cardiac
UR - http://www.scopus.com/inward/record.url?scp=85055134544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055134544&partnerID=8YFLogxK
U2 - 10.1161/CIRCRESAHA.118.311339
DO - 10.1161/CIRCRESAHA.118.311339
M3 - Article
C2 - 29903739
AN - SCOPUS:85055134544
SN - 0009-7330
VL - 123
SP - 428
EP - 442
JO - Circulation Research
JF - Circulation Research
IS - 4
ER -